



You are cordially invited to attend a live promotional presentation

THE OXERVATE® EXPERIENCE


Thursday, July 9, 2026
6:30 PM Eastern Standard Time
Boulon Brasserie
1001 Water Street, Suite #102, Tampa, FL 33602

oxervate® 
(cenegermin-bkby ophthalmic solution) 0.002% (20 mcg/mL)

This program will present ways to identify and diagnose neurotrophic keratitis and the clinical profile of OXERVATE for the treatment of NK.

PRESENTED BY: John Sheppard, Jr., MD, MMSc, FACS
Eastern Virginia Medical School
Cape Charles, VA

HOSTED BY: Bethany Boulter
bethany.boulter@dompe.com
813-810-1919



REGISTRATION:

[Click here](https://portal.pharmethod.com/dompe/register) (or visit <https://portal.pharmethod.com/dompe/register>) or **scan the QR code** to register for this live meeting. Once registered, you will receive a confirmation email from PharMethod with the meeting details.

Reference program #30274

REGISTRATION CONTACT: 813-810-1919 | bethany.boulter@dompe.com



Indication

OXERVATE is indicated for the treatment of neurotrophic keratitis (NK).¹

Important Safety Information

WARNINGS AND PRECAUTIONS

Contact lenses, either therapeutic or corrective, should be removed before applying OXERVATE. Contact lenses may be reinserted 15 minutes after OXERVATE administration.

Eye Discomfort, such as eye pain, that can be mild to moderate can occur with OXERVATE. Patients should contact their health care provider if a more serious eye reaction occurs.

ADVERSE REACTIONS

The most common adverse reaction with OXERVATE (~16%) was eye pain. Other adverse reactions with OXERVATE (1% to 10%) included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

Please read the [full Prescribing Information](http://www.oxervate.com/prescribing-information) for OXERVATE at www.oxervate.com/prescribing-information.

As of January 1, 2022, in accordance with PhRMA Code, Dompé will no longer provide nor reimburse for alcohol as part of this educational program.

We look forward to your participation at this promotional program. Program attendance is by invitation only, and we regret that this invitation cannot be forwarded.

Reference: 1. OXERVATE (cenegermin-bkby) ophthalmic solution 0.002% (20 mcg/mL) [US package insert]. San Mateo, CA; Dompé U.S. Inc.; 2024.

©2025 Dompé U.S. Inc. All rights reserved.

Dompé and the Dompé Logo are trademarks or registered trademarks of Dompé farmaceutici S.p.A.
US-OXE-2400050.1 02/25

